Nebacumab
Monoclonal antibody
![☒](http://upload.wikimedia.org/wikipedia/commons/thumb/a/a2/X_mark.svg/7px-X_mark.svg.png)
![check](http://upload.wikimedia.org/wikipedia/en/thumb/f/fb/Yes_check.svg/7px-Yes_check.svg.png)
Nebacumab is a human monoclonal antibody developed for the treatment of sepsis.[1] It has been withdrawn in 1993 because it failed to reduce mortality in clinical trials.[2]
References
- ^ Derkx B, Wittes J, McCloskey R (April 1999). "Randomized, placebo-controlled trial of HA-1A, a human monoclonal antibody to endotoxin, in children with meningococcal septic shock. European Pediatric Meningococcal Septic Shock Trial Study Group". Clinical Infectious Diseases. 28 (4): 770–7. doi:10.1086/515184. PMID 10825037.
- ^ WHO: Consolidated List of Products
- v
- t
- e
Monoclonal antibodies for infectious disease and toxins
Human |
|
---|
Human |
|
---|---|
Chimeric | |
Humanized |
Human |
|
---|---|
Mouse | |
Chimeric | |
Humanized |
Human | |
---|---|
Chimeric | |
Humanized |
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
![]() | This antiinfective drug article is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e
![]() | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e